Cytokines and Inflammatory Recruitment in NASH: Experimental and Human Studies

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 123-131

  Li, Zhiping ^a   Diehl, Anna Mae ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immune system; Insulin resistance; Nonalcoholic steatohepatitis (NASH); Norepinephrine (NE); Pathogenic mechanisms

Indexed keywords

EID: 33645218405     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch10     Document Type: Chapter

References (44)

1. Ludwig J, Viggiano RT, McGill DB. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 342-8.
2. Kamimura S, Tsukamoto H. Cytokine gene expression by Kupffer cells isolated from ethanol-fed rats. Hepatology 1995; 22: 1304-9.
3. Bird GLA, Sheron N, Goka AKJ, Alexander GL, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-20.
4. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9: 349-51.
5. Hill D, Marsano L, Cohen D et al. Increased plasma interleukin-6 activity in alcoholic hepatitis. J Lab Clin Med 1992; 119: 507-12.
6. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor-a attenuates hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26: 1530-7.
7. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-24.
8. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimentalalcoholic liver disease. Proc Soc Exp Biol Med 1994; 205: 243-7.
9. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
10. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104.
11. Kern PA, Saghizaheh M, Ong JM et al. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-9.
12. Li Z, Lin HZ, Yang SQ, Diehl AM. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002; 123: 1304-10.
13. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
14. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor a and TNF-receptors, p55 and p75, in non-alcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
15. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor a promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
16. Wigg AJ, Roberts-Thomson IC, Dymock RB et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor a in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
17. Loguercio C, DeSimone T, Federico A et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97: 2144-6.
18. Jarvelainen HA, Orpana A, Perola M et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33: 1148-53.
19. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
20. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-62.
21. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001; 15: 2565-71.
22. Zarkesh-Esfahani H, Pockley G, Metcalfe RA et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001; 167: 4593-9.
23. Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901.
24. Sanna V, Di Giacomo A, La Cava A et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003; 111: 241-50.
25. Loffreda S, Yang SQ, Lin HZ et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65.
26. Howard JK, Lord GM, Matarese G et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999; 104: 1051-9.
27. Guebre-Xabier M, Yang SQ, Lin HZ et al. Altered hepatic lymphocyte subpopulations in obesity-related fatty livers. Hepatology 1999; 31: 633-40.
28. Matsui K, Yoshimoto T, Tsutsui H et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type 1 T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 1997; 159: 97-106.
29. Makimura H, Mizuno TM, Roberts J et al. Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ob mice. Diabetes 2000; 49: 1917-23.
30. Knehans AW, Romsos DR. Reduced norepinephrine turnover in brown adipose tissue of ob/ob mice. Am J Physiol 1982; 242: E253-61.
31. Cohen P, Zhao C, Cai X et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108: 1113-21.
32. Spengler RN, Chensue SW, Giacherio DA, Blenk N, Kunkel SL. Endogenous norepinephrine regulates tumor necrosis factor-a production from macrophages in vitro. J Immunol 1994; 152: 3024-31.
33. Kalinichenko VV, Mokyr MB, Graf LH Jr, Cohen RL, Chambers DA. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a β-adrenergic receptor mechanism and decreased TNF-a gene expression. J Immunol 1999; 163: 2492-9.
34. Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-a/IL-10 balance: clinical implications. Ann NY Acad Sci 2000; 917: 94-105.
35. Zhou M, Yang S, Koo DJ et al. The role of Kupffer cell 2- adrenoceptors in norepinephrine-induced TNF-a production. Biochim Biophys Acta 2001; 1537: 49-57.
36. Minagawa M, Oya H, Yamamoto S et al. Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation. Hepatology 2000; 31: 907-15.
37. Shimizu Y, Margenthaler JA, Landeros K et al. The resistance of P. acnes-primed interferon-y-deficient mice to low-dose lipopolysaccharide-induced acute liver injury. Hepatology 2002; 35: 805-14.
38. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
39. Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat- induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46.
40. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKK-p. Science 2001; 293: 1673-7.
41. Aggarwal BB. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NK-kB. Ann Rheum Dis 2000; 59 (Suppl. 1): I6 -I16.
42. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin-resistance in mice lacking TNF-a function. Nature 1997; 389: 610-4.
43. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
44. Chitturi S, Farrell GC. Etiopathogenesis of non-alcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.